EUCTR2018-001547-32-FR进行中（未招募）1 期
A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 627
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Histologically confirmed locally advanced or metastatic NSCLC
- •2. Measurable disease by RECIST 1.1
- •3. Known PD-L1 status
- •4. ECOG performance status (PS) = 1.
- •5. Other protocol-defined inclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 314
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 313
排除标准
- •1. Previous immunotherapy or treatment with IL-1ß inhibitor.
- •2. Subjects with epidermal growth factor receptor (EGFR) sensitizing mutations and/or ALK rearrangement
- •3. History of severe hypersensitivity reaction to monoclonal antibodies, platinum containing drugs, nab-paclitaxel, paclitaxel, pemetrexed or any known excipients of these drugs
- •4. Other protocol-defined exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
16-week efficacy and 2-year safety, tolerability and efficacy of secukinumab in participants with active ankylosing spondylitisAnkylosing SpondylitisEUCTR2013-005575-41-CZovartis Pharma Services AG350
进行中（未招募）
1 期
Study of efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC subjectsEUCTR2018-001547-32-ATovartis Pharma AG673
进行中（未招募）
1 期
A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge ModelTreatment of InfluenzaMedDRA version: 20.1 Level: LLT Classification code 10022002 Term: Influenza A virus infection System Organ Class: 100000004862MedDRA version: 20.0 Level: LLT Classification code 10022001 Term: Influenza (epidemic) System Organ Class: 100000004862MedDRA version: 20.0 Level: LLT Classification code 10016790 Term: Flu System Organ Class: 100000004862EUCTR2013-001983-52-GBGenentech Inc.101
进行中（未招募）
1 期
Study of efficacy and safety of canakinumab in combination with docetaxel in subjects with non-small cell lung cancers as a second or third line therapy.on-small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002480-26-GRovartis Pharma AG244
进行中（未招募）
1 期
Study of safety and efficacy of PDR001 in combination with dabrafenib and trametinib in patients with a genetically distinct subtype of unresectable or metastatic melanoma, which is characterised by a mutation in the BRAF geneEUCTR2016-002794-35-DEovartis Pharma AG538